Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation

Tagrid Kaddar1, Jean-Pierre Rouault, Wei Wen Chien

  • 1LBMC, CNRS UMR5239, IFR128, Faculté de Médecine Lyon Sud, Université Lyon 1, Pierre Bénite, France.

Biology of the Cell
|March 3, 2009
PubMed
Abstract

Insights

MicroRNA-16 (miR-16) down-regulates cell proliferation targets, including high-mobility group A1 (HMGA1) and cytoplasmic activation/proliferation-associated protein-1 (caprin-1). This study validates HMGA1 and caprin-1 as novel miR-16 targets, impacting cell growth pathways.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are non-coding RNAs that regulate gene expression by targeting messenger RNAs (mRNAs).
  • miR-16, a specific miRNA, is implicated in cell proliferation, apoptosis, and leukaemogenesis.
  • Identifying novel miRNA targets is crucial for understanding complex gene regulatory networks.

Purpose of the Study:

  • To identify and validate novel targets of miR-16.
  • To investigate the role of miR-16 in regulating cell proliferation-associated genes.
  • To elucidate the mechanisms by which miR-16 affects target gene expression.

Main Methods:

  • Bioinformatics analysis to predict potential miR-16 targets.
  • Luciferase activity assays to confirm direct interaction of miR-16 with target 3' UTRs.
  • Western blot and quantitative PCR to assess protein and mRNA level changes.

Main Results:

  • Two novel miR-16 targets, caprin-1 and HMGA1, were identified and validated.
  • miR-16 was shown to directly bind to the 3' UTR of caprin-1, HMGA1, and cyclin E mRNAs.
  • Down-regulation of caprin-1, HMGA1 (isoforms a and b), and cyclin E at protein and mRNA levels was observed in response to miR-16.

Conclusions:

  • miR-16 negatively regulates HMGA1 and caprin-1, both involved in cell proliferation.
  • The observed inhibition of cyclin E expression is partly attributed to decreased mRNA stability.
  • These findings expand the understanding of miR-16's role in cellular processes and disease.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...